Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease

A post hoc analysis of the ZENITH-CKD trial showed adding the endothelin receptor antagonist zibotentan to dapagliflozin reduced albuminuria in CKD whether or not patients had type 2 diabetes, with fluid retention occurring mainly in those with diabetes at the higher dose.